source
- Roche CEO says stance on $1.5B Poseida acquisition unchanged despite dropping one CAR-T programRoche bought Poseida in 2024 for $1.5 billion to secure its off-the-shelf CAR-T platform and strengthen its cell-therapy portfolio. During the third-quarter earnings call, the company said it has…
- Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approvalNodThera—under its new name Rezera—is planning an IPO as the biotech steps up its ambitions to get its NLRP3 inhibitor to market.Fierce Biotech · 6h ago↗ source